Literature DB >> 11959424

An alternatively spliced form of rodent alpha-synuclein forms intracellular inclusions in vitro: role of the carboxy-terminus in alpha-synuclein aggregation.

Pamela J McLean1, Bradley T Hyman.   

Abstract

In the rat, the -synuclein gene is alternatively spliced and exists in three forms, rat synuclein 1 (rSYN1), synuclein 2 (rSYN2) and synuclein 3. rSYN2 cDNA encodes a 149 amino acid protein that is homologous to rSYN1 and human -synuclein for the first 100 amino acids, but is divergent for the 49 amino acid carboxy-terminal region. We demonstrate here that rSYN2 forms small aggregates throughout the cytoplasm when overexpressed in human H4 cells, whereas rSYN1 expression is diffuse. Inhibition of the proteasome promotes the formation of larger, cytoplasmic rSYN2 inclusions in transfected cells. Although a survey of the available databases suggests that there is no human splice form equivalent of rSYN2, thus arguing against a direct role in Lewy body formation and Parkinson's disease, these data nonetheless suggest that modifications of the carboxy-terminal region of -synuclein predispose it to inclusion formation.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11959424     DOI: 10.1016/s0304-3940(02)00154-4

Source DB:  PubMed          Journal:  Neurosci Lett        ISSN: 0304-3940            Impact factor:   3.046


  14 in total

Review 1.  Drug targets from genetics: α-synuclein.

Authors:  Karin M Danzer; Pamela J McLean
Journal:  CNS Neurol Disord Drug Targets       Date:  2011-09-01       Impact factor: 4.388

2.  Physiological C-terminal truncation of α-synuclein potentiates the prion-like formation of pathological inclusions.

Authors:  Zachary A Sorrentino; Niran Vijayaraghavan; Kimberly-Marie Gorion; Cara J Riffe; Kevin H Strang; Jason Caldwell; Benoit I Giasson
Journal:  J Biol Chem       Date:  2018-10-16       Impact factor: 5.157

Review 3.  Dynamic Protein Interaction Networks and New Structural Paradigms in Signaling.

Authors:  Veronika Csizmok; Ariele Viacava Follis; Richard W Kriwacki; Julie D Forman-Kay
Journal:  Chem Rev       Date:  2016-02-29       Impact factor: 60.622

Review 4.  The emerging role of α-synuclein truncation in aggregation and disease.

Authors:  Zachary A Sorrentino; Benoit I Giasson
Journal:  J Biol Chem       Date:  2020-05-18       Impact factor: 5.157

5.  Transcript expression levels of full-length alpha-synuclein and its three alternatively spliced variants in Parkinson's disease brain regions and in a transgenic mouse model of alpha-synuclein overexpression.

Authors:  Jesse R McLean; Penelope J Hallett; Oliver Cooper; Michael Stanley; Ole Isacson
Journal:  Mol Cell Neurosci       Date:  2011-12-06       Impact factor: 4.314

6.  The effect of truncation on prion-like properties of α-synuclein.

Authors:  Makoto Terada; Genjiro Suzuki; Takashi Nonaka; Fuyuki Kametani; Akira Tamaoka; Masato Hasegawa
Journal:  J Biol Chem       Date:  2018-07-20       Impact factor: 5.157

7.  SRRM2, a potential blood biomarker revealing high alternative splicing in Parkinson's disease.

Authors:  Lina A Shehadeh; Kristine Yu; Liyong Wang; Alexandra Guevara; Carlos Singer; Jeffery Vance; Spyridon Papapetropoulos
Journal:  PLoS One       Date:  2010-02-08       Impact factor: 3.240

Review 8.  Alpha-synuclein post-translational modifications as potential biomarkers for Parkinson disease and other synucleinopathies.

Authors:  Adrien W Schmid; Bruno Fauvet; Marc Moniatte; Hilal A Lashuel
Journal:  Mol Cell Proteomics       Date:  2013-08-21       Impact factor: 5.911

9.  The loss of inhibitory C-terminal conformations in disease associated P123H β-synuclein.

Authors:  Maria K Janowska; Jean Baum
Journal:  Protein Sci       Date:  2015-09-21       Impact factor: 6.725

10.  Oxidants induce alternative splicing of alpha-synuclein: Implications for Parkinson's disease.

Authors:  Shasi V Kalivendi; Deepthi Yedlapudi; Cecilia J Hillard; B Kalyanaraman
Journal:  Free Radic Biol Med       Date:  2009-10-23       Impact factor: 7.376

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.